Short Sellers Raise the Stakes in Major Biotechs
The January 12 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 146
SunTrust Bullish on Blue Chip Large-Cap Pharmaceuticals: 4 to Buy Now
With the market trading at very extended valuations, and the S&P 500 on the longest streak ever without a 5% correction, it may make sense to move to some safer higher ground.
Why Analysts Are Slashing Their Targets for Puma Biotechnology
Puma Biotechnology saw its shares take a dive on Wednesday following regulatory events in Europe for its breast cancer treatment.
Solid Biosciences Closes in on IPO With Updated Pricing
Solid Biosciences intends to price its 7 million shares so that its initial public offering is valued up to nearly $153 million.
Johnson & Johnson Takes on $14 Billion Tax Charge With Q4 Earnings
Johnson & Johnson reported better-than-expected fourth-quarter financial results before the markets opened on Tuesday.
Analyst Has 4 Buy-Rated Medical Stocks That Pay Massive Dividends
Out of favor and facing some headwinds, the medical real estate investment trusts are offering some outstanding value at current levels.
Nymox Pharmaceutical Screams Higher on Prostate Cancer Study
Nymox Pharmaceutical watched its shares make a solid gain on Monday after the firm announced five-year results from its prostate cancer study.
Sanofi Moves to Acquire Bioverativ
Bioverativ is adding to Monday’s M&A news after it was announced that Sanofi would be acquiring the firm.
Why Celgene Is Betting Big on 2020 With Juno Acquisition
Juno Therapeutics saw its shares take off early on Monday after it was announced that Celgene would be acquiring it.
Menlo Therapeutics Closes in on IPO
Menlo Therapeutics plans on pricing its more than 5 million shares in a range that results in an initial public offering valued up to more than $104 million.
Credit Suisse Outlines Top Biotech M&A Targets and Catalyst Stocks for 2018
Credit Suisse sees tax reform sparking a wave of mergers in the emerging pharmaceuticals space, which could produce sector outperformance. The firm is cautiously optimistic on this front.
Investors Cheer BeiGene’s Secondary Offering
BeiGene saw its shares make a handy gain on Thursday after the company announced that it would be conducting a secondary offering.
Exelixis Slides Despite Positive Late-Stage Results
Shares of Exelixis slipped on Wednesday after the company reported results from its late-stage trial of cabozantinib for advanced hepatocellular carcinoma.
ARMO Announces Potential Pricing for IPO
ARMO BioSciences intends to price more than 6. million shares in a range that results in an initial public offering valued up to more than $122 million.
Why Juno Therapeutics Is Soaring
Juno Therapeutics saw its shares skyrocket early on Wednesday after reports that Celgene was in talks to acquire the company.